ECOR icon

electroCore

15.27 USD
+0.75
5.17%
At close Dec 20, 4:00 PM EST
1 day
5.17%
5 days
12.20%
1 month
53.62%
3 months
136.38%
6 months
149.92%
Year to date
155.78%
1 year
164.19%
5 years
-17.15%
10 years
-94.87%
 

About: electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.

Employees: 62

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

250% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 2

8% more capital invested

Capital invested by funds: $6.61M [Q2] → $7.15M (+$545K) [Q3]

7.0% more ownership

Funds ownership: 16.49% [Q2] → 23.49% (+7.0%) [Q3]

0% more funds holding

Funds holding: 22 [Q2] → 22 (+0) [Q3]

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$25
64%
upside
Avg. target
$25
64%
upside
High target
$25
64%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Swayampakula Ramakanth
30% 1-year accuracy
52 / 173 met price target
64%upside
$25
Buy
Maintained
18 Dec 2024

Financial journalist opinion

Neutral
GlobeNewsWire
4 days ago
electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness
The Quell® platform will strengthen our position as a significant player in the bioelectronic health and wellness sector
electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness
Neutral
GlobeNewsWire
1 month ago
electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21
ROCKAWAY, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum taking place in New York City on November 21, 2024.
electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21
Neutral
Seeking Alpha
1 month ago
electroCore, Inc. (ECOR) Q3 2024 Earnings Call Transcript
electroCore, Inc. (NASDAQ:ECOR ) Q3 2024 Earnings Call Transcript November 13, 2024 4:30 PM ET Company Participants Dan Goldberger - CEO & Director Joshua Lev - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Swayampakula Ramakanth - H.C. Wainwright Operator Greetings, and welcome to the electroCore Third Quarter 2024 Earnings Conference Call.
electroCore, Inc. (ECOR) Q3 2024 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
ElectroCore, Inc. (ECOR) Reports Q3 Loss, Tops Revenue Estimates
ElectroCore, Inc. (ECOR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.68 per share a year ago.
ElectroCore, Inc. (ECOR) Reports Q3 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
1 month ago
electroCore Announces Third Quarter 2024 Financial Results
Record quarterly revenues driven by 75% YoY growth of Rx gammaCore™ in the VA/DoD and 147% increase in Truvaga™ sales
electroCore Announces Third Quarter 2024 Financial Results
Neutral
GlobeNewsWire
1 month ago
ElectroCore's Truvaga™ Plus Wins Men's Health Magazine Tech Award
ROCKAWAY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, is proud to announce that its flagship wellness product, Truvaga Plus, has been awarded the prestigious Men's Health Magazine Tech Award for a pioneering wellness device recognized for innovation and excellence. The award celebrates groundbreaking advancements in health and technology and highlights products that significantly impact men's health and wellness. A link to the article can be found here: Men'sHealth Tech Awards 2025.
ElectroCore's Truvaga™ Plus Wins Men's Health Magazine Tech Award
Positive
Zacks Investment Research
1 month ago
Strength Seen in electroCore (ECOR): Can Its 6.0% Jump Turn into More Strength?
electroCore (ECOR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Strength Seen in electroCore (ECOR): Can Its 6.0% Jump Turn into More Strength?
Neutral
GlobeNewsWire
1 month ago
electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
ROCKAWAY, N.J., Nov. 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Thomas Freeburg will join electroCore, effective November 11, 2024, as the Company's VP, Corporate Controller. The Compensation Committee of electroCore's Board of Directors granted 5,000 restricted stock units (“RSUs”) to Mr. Freeburg in connection with the commencement of his employment. The RSUs were granted as an inducement material to Mr. Freeburg's commencement of employment pursuant to NASDAQ Listing Rule 5635(c)(4). 33% of the RSUs will vest on each of the first, second and third anniversaries of the date of grant, subject to Mr. Freeburg's continued employment by the Company on the applicable vesting date. Upon vesting, the RSUs shall be settled in shares of the Company's common stock.
electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
Positive
Zacks Investment Research
1 month ago
electroCore (ECOR) Stock Jumps 11.7%: Will It Continue to Soar?
electroCore (ECOR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
electroCore (ECOR) Stock Jumps 11.7%: Will It Continue to Soar?
Neutral
Newsfile Corp
2 months ago
electroCore to Participate at LD Micro Main Event VXII
Rockaway, New Jersey--(Newsfile Corp. - October 14, 2024) - electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the LD Micro Main Event XVII on Tuesday, October 29 at 4:30 p.m. PT at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.
electroCore to Participate at LD Micro Main Event VXII
Charts implemented using Lightweight Charts™